Pharmaceutical company Amneal Pharmaceuticals Inc (NYSE:AMRX) reported on Monday the receipt of final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDA) for generic versions of Revatio (sildenafil citrate) and Amicar (aminocaproic acid).
Following the US FDA approval, the company has initiated the commercialization activities for Revatio for oral suspension in 10 mg/ml and Amicar tablets USP in 500 mg.
The company has received the US FDA Competitive Generic Therapy (CGT) designation for the generic version of Amicar and under the first approved application, the tablet has been granted with 180 days of CGT exclusivity.
For the 12 months ended 30 September 2019, the US market annual sales for the company's sildenafil citrate oral suspension and aminocaproic acid 500 mg tablets were estimated at about USD180m and USD23m, respectively, according to IQVIA,
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US